Century Therapeutics (IPSC) Set to Release Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC) is projected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $1.63 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, analysts expect Century Therapeutics to post ($0.51) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $1.67 on Thursday. The firm has a market capitalization of $302.39 million, a PE ratio of -1.80 and a beta of 1.78. The business has a 50 day simple moving average of $1.70 and a two-hundred day simple moving average of $2.08. Century Therapeutics has a 1 year low of $0.43 and a 1 year high of $3.04.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IPSC. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research note on Tuesday, September 29th. Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Century Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.75.

About Century Therapeutics

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.